Trials / Completed
CompletedNCT01827943
Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer
Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Institut Bergonié · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival.
Detailed description
In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival. This study will also search for genes involved in the response to treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Temsirolimus | Temsirolimus |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2014-12-01
- Completion
- 2016-12-01
- First posted
- 2013-04-10
- Last updated
- 2021-05-06
- Results posted
- 2021-04-09
Locations
9 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01827943. Inclusion in this directory is not an endorsement.